Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Large B-Cell, Diffuse 16 Lymphoma, Mantle-Cell 10 Recurrence 9 Lymphoma, Non-Hodgkin 8 Lymphoma, B-Cell 7 Lymphoma 7 Dendritic Cell Sarcoma, Interdigitating 4 Neoplasms 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Immunoblastic Lymphadenopathy 1 Cytokine Release Syndrome 1 Ann Arbor Stage II Mantle Cell Lymphoma 1 Aggression 1

Interventions

glofitamab 1 Positron Emission Tomography Computed Tomography 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Aggression × glofitamab × 1 year × Clear all

NCT06534437 2025-09-29

JASPIS-01

Ryvu Therapeutics SA

Phase 2 Recruiting

Aggression, Lymphoma, Non-Hodgkin, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡